Table 1. GBM patients’ characteristics and tumors analysis for B-cell infiltration.

A total of 60 GBM patients’ tumor samples were tested for the presence of CD20⁺ B cells by IHC. Patients were stratified (variable) by age, gender, newly diagnosed or recurrent, isocitrate dehydrogenase (IDH) mutation and O[6]-methylguanine-DNA methyltransferase (MGMT) methylation status, CD8⁺ T-cell infiltration and location. These variables were analyzed for statistical correlation with presence or not of B cells (p-value).

Variable	B-cell present N=25	B-cell NOT present N=37	P-value
Age at diagnosis (yrs)
N	25	37	0.1778
Mean(SD)	52.72 (15.31)	57.78 (13.66)	.
Median(Q1,Q3)	54 (40,66)	62 (51,68)	.
Minimum, Maximum	23–77	27–86	.
Gender
MALE	19 (76%)	25 (67.57%)	0.5740
FEMALE	6 (24%)	12 (32.43%)	.
New or Recurrence
New	18 (72%)	25 (67.57%)	0.7840
Recurrence	7 (28%)	12 (32.43%)	.
IDH1 Mutation			0.4683
Yes	5 (20%)	6 (16.22%)	.
No	20 (80%)	30 (81.08%)	.
Unknown	0	1 (2.7%)	.
MGMT Methylation			0.3762
Positive	9 (36%)	20 (54.05%)	.
Negative	15 (60%)	16 (43.24%)	.
N/A	1 (4%)	1 (2.71%)	.
Associated with CD8
Yes	25 (100%)	0 (0%)	<0.0001
No	0 (0%)	37 (100%)	.
Location
Perivascular	23 (92%)	0 (0%)	.
Perivascular intraparenchymal	2 (8%)	0 (0%)	.